For some, perhaps getting patents in India just isn’t worth the hassle anymore
Roche announced last week that it is allowing the Indian patent covering its breast cancer treatment Trastuzumab – marketed under the brand name of Herceptin – to expire. If other life sciences companies follow suit and decide that Indian patents…
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Register now
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
Subscribe now